XML 73 R6.htm IDEA: XBRL DOCUMENT v3.25.2
CONSOLIDATED STATEMENTS OF EQUITY - USD ($)
$ in Thousands
Total
Total Lisata Therapeutics, Inc. Stockholders' Equity
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Treasury Stock
Non- Controlling Interest in Subsidiary
Common stock, beginning balance (in shares) at Dec. 31, 2023     8,151,000          
Beginning balance at Dec. 31, 2023 $ 47,894 $ 48,148 $ 8 $ 576,971 $ (42) $ (528,081) $ (708) $ (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (10,445) (10,445)       (10,445)    
Share-based compensation (in shares)     157,000          
Share-based compensation 549 549   549        
Net proceeds from issuances of common stock (in shares)     14,000          
Net proceeds from issuances of common stock 32 32   32        
Unrealized gain (loss) on marketable securities (9) (9)     (9)      
Foreign currency translation adjustment (26) (26)     (26)      
Common stock, ending balance (in shares) at Jun. 30, 2024     8,322,000          
Ending balance at Jun. 30, 2024 37,995 38,249 $ 8 577,552 (77) (538,526) (708) (254)
Common stock, beginning balance (in shares) at Mar. 31, 2024     8,308,000          
Beginning balance at Mar. 31, 2024 42,743 42,997 $ 8 577,283 (104) (533,482) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (5,044) (5,044)       (5,044)    
Share-based compensation 237 237   237        
Net proceeds from issuances of common stock (in shares)     14,000          
Net proceeds from issuances of common stock 32 32   32        
Unrealized gain (loss) on marketable securities 4 4     4      
Foreign currency translation adjustment 23 23     23      
Common stock, ending balance (in shares) at Jun. 30, 2024     8,322,000          
Ending balance at Jun. 30, 2024 $ 37,995 38,249 $ 8 577,552 (77) (538,526) (708) (254)
Common stock, beginning balance (in shares) at Dec. 31, 2024 8,408,844   8,410,000          
Beginning balance at Dec. 31, 2024 $ 29,317 29,571 $ 8 578,418 (81) (548,066) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (9,383) (9,383)       (9,383)    
Share-based compensation (in shares)     129,000          
Share-based compensation 516 516   516        
Net proceeds from issuances of common stock (in shares)     84,000          
Net proceeds from issuances of common stock $ 286 286 $ 1 285        
Proceeds from option exercises (in shares) 4,329   4,000          
Proceeds from option exercises $ 8 8   8        
Unrealized gain (loss) on marketable securities 3 3     3      
Foreign currency translation adjustment $ 28 28     28      
Common stock, ending balance (in shares) at Jun. 30, 2025 8,626,464   8,627,000          
Ending balance at Jun. 30, 2025 $ 20,775 21,029 $ 9 579,227 (50) (557,449) (708) (254)
Common stock, beginning balance (in shares) at Mar. 31, 2025     8,621,000          
Beginning balance at Mar. 31, 2025 25,102 25,356 $ 9 578,923 (78) (552,790) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (4,659) (4,659)       (4,659)    
Share-based compensation (in shares)     (22,000)          
Share-based compensation 230 230   230        
Net proceeds from issuances of common stock (in shares)     28,000          
Net proceeds from issuances of common stock 74 74   74        
Unrealized gain (loss) on marketable securities 4 4     4      
Foreign currency translation adjustment $ 24 24     24      
Common stock, ending balance (in shares) at Jun. 30, 2025 8,626,464   8,627,000          
Ending balance at Jun. 30, 2025 $ 20,775 $ 21,029 $ 9 $ 579,227 $ (50) $ (557,449) $ (708) $ (254)